Riskpilot← Back to searchSign inGet full accessOptifys AB
ABActiveOrg 5568244981Inteckningsvägen 17 G Lgh 1401Other human health activities n.e.c. · NACE 8699Est. 20101-4 employees
Revenue 2024
SEK 645K
+73% vs 2023
EBITDA margin
-106.7%
+29% vs 2023
Equity ratio
73.2%
Financial strength
Net profit 2024
SEK 413K
+285% vs 2023
| Revenue | SEK 645K | +73% |
| EBITDA | SEK -688K | +29% |
| Net profit | SEK 413K | +285% |
| Total assets | SEK 1,9M | +17% |
| Equity | SEK 1,4M | +13% |
| Employees | — | — |
Legal name
Optifys AB
Org number
5568244981
Legal form
Aktiebolag
NACE code
8699 · Other human health activities n.e.c.
Founded
9 november 2010
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva medicinska föreläsningar, fysiologisk rådgivning och konsultation, hälsovård och vård inom läkarbranschen, samt därmed förenlig verksamhet.
Address
Inteckningsvägen 17 G Lgh 1401
Email
per.pliggen@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 647 | 2 183 | 2 367 | 373 | 645 |
| Staff expenses | — | −606 | −622 | −826 | −712 |
| EBITDA | 675 | 924 | 924 | −966 | −688 |
| Depreciation & amort. | −110 | −105 | −100 | −112 | −112 |
| EBIT | 565 | 818 | 824 | −1 078 | −800 |
| Net financials | −1 | −0 | −1 | 0 | 1 213 |
| Profit before tax | 414 | 818 | 698 | −223 | 413 |
| Tax | −101 | −181 | −180 | — | — |
| Net profit | 313 | 638 | 518 | −223 | 413 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 353 | 3 004 | 3 050 | 1 612 | 1 881 |
| Equity | 1 396 | 1 834 | 1 792 | 1 219 | 1 377 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 226 | 440 | 403 | 393 | 504 |
| Total debt | 226 | 440 | 403 | 393 | 504 |
EBITDA margin
-106.7%
This company
15.8%
Market median
-775% vs market
20202024
Equity ratio
73.2%
This company
38.2%
Market median
+92% vs market
20202024
Return on equity
30.0%
This company
18.4%
Market median
+63% vs market
20202024
Net profit margin
64.0%
This company
8.1%
Market median
+690% vs market
20202024
Asset turnover
0.34×
This company
1.12×
Market median
-70% vs market
20202024
Debt / equity
0.37×
This company
0.62×
Market median
+40% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PO Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Optifys AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Olof Andersson | Chief Executive Officer | 0 companies |
| I Andrea A C Andersson | Deputy Board Member | 0 companies |
| Lars Olof Andersson | Deputy Board Member | 0 companies |